PPT-Advanced Insulin Therapy: Achieving Better PPG Control in T1DM and T2DM

Moderator Stephen Atkin MBBS MD PhD Professor of Medicine Weill Cornell Medicine Qatar Education City Qatar Foundation Doha Qatar Faculty Tim Heise MD Lead Scientist Science and Administration. Martin J. Abrahamson, MD FACP. Associate Professor of Medicine, Harvard Medical School. Senior Vice President for Medical Affairs, Joslin Diabetes Center. Questions to Ask. Is hyperglycemia associated with increased morbidity/mortality in acutely ill patients?. of Type 1 Diabetes. Type 1 Diabetes Mellitus. Characterized by absolute insulin deficiency. Pathophysiology and etiology. Result of pancreatic beta cell destruction. Prone to ketosis. Total deficit of circulating insulin. Care of Patients with Diabetes Mellitus. Insulin Physiology. Types of Diabetes. Type I . Type 2 . Gestational Diabetes (GDM). Other specific conditions resulting in hyperglycemia. Absence of Insulin. Add on to insulin. EFFICACY AND TOLERABILITY. OF GLP-1 RECEPTOR AGONISTS. AND DPP-4 INHIBITORS AS ADDON THERAPY TO INSULIN . Complementing Insulin Therapy to Achieve Glycemic. Control. Anthony H. Barnett . Insulin Physiology. Types of Diabetes. Type I . Type 2 . Gestational Diabetes (GDM). Other specific conditions resulting in hyperglycemia. Absence of Insulin. . Hyperglycemia. Polyuria. Polydipsia. Polyphagia. Disease. . s_khalilzadeh. A Novel. Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic. syndrome and is regarded as the hepatic manifestation. SGLT Inhibitors. Program Overview. Glycemic Control in T1DM. Risks Associated With T1DM. Limitations of Insulin Therapy for T1DM. Noninsulin Therapy for T1DM: Pramlintide. T2DM Therapies for T1DM: Metformin. Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors Introduction/Overview Intensive Therapy Reduces Diabetes Complications Rates Variability in Time-Action Profile of Basal Insulins* Basal Bolus versus Premixed . ADA Diabetes Management Algorithm 2015 . Need for Early and aggressive treatment. Legacy effect: early vs late glycemic control and complications risk. Aggressive glycemic control:. By . Dr.Tamara. . Kufoof. MBBS, Assistant Professor, . Pediatric Endocrinologist and Diabetologist, The Hashemite University. 2021/2022. Diabetes mellitus (DM) . . a common, chronic, metabolic disease characterized by . Dr . Waqar. Malik. Consultant . Diabetologist. Blakesley. Hall, . Blakesley. Road, Birmingham. 9. th. Jan. 2017. Lay Out. Why glycaemic control is important and what role insulin plays. Different insulins old and new. Tom Heaps. Consultant Acute Physician. Case 1. 82-year-old Caucasian female with T2DM (>30 years) and HTN. BMI 19. Metformin. 500mg TDS , . Gliclazide. 40mg BD, . Ramipril. 5mg OD. Admitted with 1/52 of increasing drowsiness, confusion and reduced oral intake. What Follows Metformin? . James R. Gavin III, MD, PhD. CEO & Chief Medical Officer, Healing Our Village, Inc.. Clinical Professor of Medicine. Emory University, School of Medicine. Atlanta, Georgia USA. David J. Robinson • Michael J. Coons • Jean-François Yale. Valerie H. Taylor • Gail M. MacNeill • Ronald M. Goldenberg. St. Michael’s Hospital, Toronto, Ontario, Canada. 12. th. May 2017.